Free Trial

ImmuCell Q2 2024 Earnings Report

ImmuCell logo
$4.41 -0.17 (-3.71%)
(As of 12/20/2024 05:51 PM ET)

ImmuCell EPS Results

Actual EPS
-$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ImmuCell Revenue Results

Actual Revenue
$5.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImmuCell Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

ImmuCell Earnings Headlines

ImmuCell Reports Strong Sales Growth in Q3 2024
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
See More ImmuCell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email.

About ImmuCell

ImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

View ImmuCell Profile

More Earnings Resources from MarketBeat

Upcoming Earnings